Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood that progresses quickly without treatment. It affects mostly cells that aren’t fully developed. These cells can’t carry out their normal functions. That’s one reason why it’s important to get care and treatment as soon as possible.
With treatment, people who have AML continue to see improved results. However, AML can be a difficult disease to treat, and researchers are studying new approaches to AML therapy in clinical trials.
AML is also called:
acute myelogenous leukemia
acute myelocytic leukemia
acute myeloblastic leukemia
acute granulocytic leukemia
Source: Leukemia & Lymphoma Society’s booklet, Acute Myeloid Leukemia.
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow and blood that progresses rapidly without treatment. That’s why it’s important to start treatment soon after diagnosis.
Most children with ALL are cured of their disease after treatment. The numbers of adults and their remission lengths have grown significantly over the past 30 years.
Source: Leukemia & Lymphoma Society’s booklet, Acute Lymphoblastic Leukemia.
Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is a type of blood cancer that begins in the bone marrow. It can progress either slowly or quickly depending on the form it takes. Many people with CLL live good-quality lives for years with medical care.
Source: Leukemia & Lymphoma Society’s booklet, Chronic Lymphocytic Leukemia.
Non-Hodgkin’s lymphoma (NHL) isn’t just one disease. It’s actually a diverse group of blood cancers that share a single characteristic in how they develop. NHL generally develops in the lymph nodes and lymphatic tissues. In some cases, NHL involves bone marrow and blood.
Source: Leukemia & Lymphoma Society’s booklet, Non-Hodgkin Lymphoma.
The term “myelodysplastic syndromes” (MDS) is used to describe a group of diseases of the blood and bone marrow, with varying degrees of severity, treatment needs and life expectancy.
MDS may be primary (de novo) or treatment-related. Primary MDS has no obvious cause. Treatment-related MDS has an obvious cause. MDS may also secondary to benzene exposure.
Source: Leukemia & Lymphoma Society’s booklet, Myelodysplastic Syndromes.